• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>American Chemical Society(ACS) National Meeting; 20020408-20020410; Orlando,FL; US >Thorium-229 for Medical Applications
【24h】

Thorium-229 for Medical Applications

机译：用于医疗的Thorium-229

获取原文
获取原文并翻译 | 示例
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Medical researchers are assessing the ability of several alpha-emitting radioisotopes to treat cancer and reduce tumor burden. In particular, ~(213)Bi (t_(1/2) = 45.6 min) attached to tumor specific antibodies has been under clinical investigations for treatment of certain cancers. ~(213)Bi is a decay product of ~(225)Ac (t_(1/2) = 10.0 d), itself an alpha emitter. Currently the domestically-produced supply of ~(225)Ac, however, is limited by the availability of the parent radionuclide, ~(229)Th (t_(1/2) = 7340 y). ~(229)Th, in turn, is a decay product of highly fissile ~(233)U, which is currently stored at ORNL and is now scheduled for long-term storage. In this paper we describe the primary separation of ~(229)Th from ~(233)U stockpile and further purification of this radioisotope from trace levels of uranium and plutonium. The chemical separation process is primarily based on the well known chemical behavior of these actinides on anion-exchange resins in both nitric and hydrochloric acid solutions.
机译：医学研究人员正在评估几种发射α的放射性同位素治疗癌症和减轻肿瘤负担的能力。尤其是，已经在临床研究中研究了与肿瘤特异性抗体连接的〜（213）Bi（t_（1/2）= 45.6分钟），以治疗某些癌症。 〜（213）Bi是〜（225）Ac（t_（1/2）= 10.0 d）的衰减产物，它本身是一个alpha发射器。但是，目前国内生产的〜（225）Ac的供应受到母体放射性核素〜（229）Th（t_（1/2）= 7340 y）的可用性的限制。反过来，〜（229）Th是高易裂变〜（233）U的衰变产物，它目前存储在ORNL中，现在已计划长期存储。在本文中，我们描述了从〜（233）U储备中初步分离〜（229）Th以及从痕量铀和p中进一步纯化该放射性同位素的方法。化学分离过程主要基于这些act系元素在硝酸和盐酸溶液中在阴离子交换树脂上的众所周知的化学行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号